Special Issue "Drug Candidates Target HTLV-1 and HTLV-1-Related Diseases"
Deadline for manuscript submissions: 25 March 2024 | Viewed by 1032
Interests: HTLV-1; adult T-cell leukemia/Lymphoma (ATLL); HTLV-1-associated myelopathic/tropical spastic paraparesis (HAM/TSP); Immunology
Interests: HTLV-1; integrase; integration; intasome assembly; PP2A-B56; integrase inhibitors
Special Issues, Collections and Topics in MDPI journals
Estimates indicate that more than 10 million individuals live with human T-cell lymphotropic virus type 1 (HTLV-1) worldwide. HTLV-1 is a retrovirus responsible for highly aggressive neoplastic diseases, such as adult T-cell leukemia/Lymphoma (ATLL), and inflammatory diseases as HTLV-1-associated myelopathic/tropical spastic paraparesis (HAM/TSP). Despite the advances in understanding the pathogenesis of HTLV-1, there is still a need to develop more effective therapies. ATLL carriers have a poor prognosis for disease evolution and a low life expectancy. These patients usually receive combined chemotherapy, but the infected cells are resistant to a large part of the cell death-inducing agents. Moreover, asymptomatic people living with HTLV-1 or carriers of HTLV-1-related diseases are treated against some symptoms using corticosteroids. However, some new compounds or drug repositioning and immunotherapy have been described with treatment promising for HTLV-1-related disease. In addition, there is promise to use antiretrovirals as a pre-exposure prophylaxis. The aim of this Special Issue is to compilate the new findings in this area.
Dr. Juliana Echevarria Neves de Lima
Dr. Goedele N. Maertens
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- adult T-cell leukemia/Lymphoma (ATLL)
- HTLV-1-associated myelopathic/tropical spastic paraparesis (HAM/TSP)
- new compounds
- drug repositing and immunotherapy